852 DAPAGLIFOZIN IN PATIENTS WITH CARDIAC HEART FAILURE
| Autor: | Norman Lamaida, Antonio Cerciello |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | European Heart Journal Supplements. 24 |
| ISSN: | 1554-2815 1520-765X |
| DOI: | 10.1093/eurheartjsupp/suac121.150 |
| Popis: | Dapaglifozin on diastolic function in patients with type 2 diabetic mellitus and chronic heart failure Heart failure (HF) with reduced ejection fraction (HFrEF) remains a challenging problem due to its high mortality rate. Another novelty in HF therapy is dapagliflozin, a sodium-glucose transporter-2 inhibitor (SGLT2i) which decreased the rates of cardiac death and worsening of HF in the DAPA-HF trial, when added in other guideline recommended therapy. Material and methods A prospective cohort study of 30 symptomatic HF patients with EF < 35% (aged 65 ±10 years) (20 males and 10 females) was conducted. Diabetic (2TDM) patients of NYHA status II–III, previously treated with ARNI, β-blocker, and mineralocorticoid receptor antagonists (MRA) were included. Dapagliflozin 10 mg was added as an adjunct therapy for 2TDM but also as a novel therapy of HF in diabetic patients. Clinical examination and complete echocardiographic evaluation were performed at baseline and 30 days after the addition of SGLT2i to their treatment. 2D echocardiography and Doppler measurements were used for the evaluation of left ventricular function, and more specifically, peak early (E-wave) and late (A-wave) transmitral filling velocities and their ratio E/A, deceleration time of E velocity (DTE). To classify diastolic dysfunction according to the ASE/EACVI guidelines published in 2016, transmitral E and A waves velocities, septal and lateral E’ tissue velocities, indexed left atrium volume and peak velocity of tricuspid regurgitation were collected. Results After 30 days of therapy with dapagliflozin, blood pressure was reduced significantly and the echocardiographic parameters of diastolic function were improved. More specifically, after 6.1±3.6 months of treatment E/A ratio decreased from 1.7 ±1.5 to 1.01±0.70 (P Discussion Our data support the evidence that SGLT2i ameliorate both the conventional echocardiographic indexes of diastolic function and this effect is noted quite promptly. The ratio of early diastolic transmitral flow velocity seems to correlate well with LV filling pressures, and may be use das a prognostic tool in patients with HFrEF. We have to emphasize that the diastolic function improvement was observed 30 days after the initiation of dapagliflozin treatment, and thus it may be considered an early marker of improvement and adequacy of treatment apart from BNP. Conclusions in this study classical diastolic echocardiographic parameters were improved promptly after initiation of dapagliflozin therapy. The ratio of early diastolic transmitral flow velocity at the early filling phase of diastole (E/SRE) may be considered a reliable index of HF therapy responders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|